270 related articles for article (PubMed ID: 26722452)
21. CD44 is of functional importance for colorectal cancer stem cells.
Du L; Wang H; He L; Zhang J; Ni B; Wang X; Jin H; Cahuzac N; Mehrpour M; Lu Y; Chen Q
Clin Cancer Res; 2008 Nov; 14(21):6751-60. PubMed ID: 18980968
[TBL] [Abstract][Full Text] [Related]
22. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Roudi R; Korourian A; Shariftabrizi A; Madjd Z
Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
Sabet MN; Rakhshan A; Erfani E; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
[TBL] [Abstract][Full Text] [Related]
24. [Biological characteristics of highly tumorigenic CD44+CD133+ subpopulation of laryngeal carcinoma cells].
Yu D; Jin CS; Chen O; Wen LJ; Gao LF
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):99-103. PubMed ID: 19538883
[TBL] [Abstract][Full Text] [Related]
25. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
26. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
Veselska R; Hermanova M; Loja T; Chlapek P; Zambo I; Vesely K; Zitterbart K; Sterba J
BMC Cancer; 2008 Oct; 8():300. PubMed ID: 18925963
[TBL] [Abstract][Full Text] [Related]
27. Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia.
Liu W; Wu L; Shen XM; Shi LJ; Zhang CP; Xu LQ; Zhou ZT
Int J Cancer; 2013 Feb; 132(4):868-74. PubMed ID: 22782852
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
29. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of cancer stem cells in ovarian yolk sac tumors.
Suzuki S; Terauchi M; Umezu T; Kajiyama H; Shibata K; Nawa A; Kikkawa F
Cancer Sci; 2010 Oct; 101(10):2179-85. PubMed ID: 20804503
[TBL] [Abstract][Full Text] [Related]
31. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
[TBL] [Abstract][Full Text] [Related]
33. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
[TBL] [Abstract][Full Text] [Related]
36. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
37. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493
[TBL] [Abstract][Full Text] [Related]
39. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
40. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
